This is a summary of the European public assessment report (EPAR) for Menveo. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Menveo.
Therapeutic Indication
**Vials** Menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07AH08
ATC Item
N/A
Pharmacotherapeutic Group
Bacterial vaccines
Active Substance (Summary)
INN / Common Names
EMA Name
Menveo
Medicine Name
Menveo
Aliases
N/ANo risk management plan link.
